leadf
logo-loader
viewImmuPharma PLC

Immupharma PLC - Update : FDA confirms 4 Dec for Type ‘A’ meeting

RNS Number : 9464F
Immupharma PLC
20 November 2020
 

 

 

 

20 November 2020

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

FDA confirms 4 December 2020 for Type 'A' meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients

 

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an update on the announcement issued on 10 November 2020, in respect to the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus ("SLE"), a potentially life-threatening auto-immune disease.

 

The US Food & Drug Administration ("FDA") has now confirmed the date of 4 December 2020 for a Type 'A' Meeting Request, with Avion Pharmaceuticals ("Avion"), ImmuPharma's licensing partner for Lupuzor™.

 

As part of the Type 'A' Meeting, Avion has asked the FDA for guidance on the following:

·    Key aspects of the study design, clinical end points and approval process for Lupuzor™; and

·    Consideration by the FDA for a conditional approval of Lupuzor™, whilst the Phase 3 trial is underway.

 

ImmuPharma will provide an update as soon as Avion has met with the FDA and notified ImmuPharma of the outcome.

 

Commenting on the announcement, Dimitri Dimitriou, CEO of ImmuPharma said:

 

"ImmuPharma and Avion are delighted that the FDA are expediting the Type 'A' Meeting for early December 2020.  We look forward to providing a further update to the market following confirmation from Avion of the FDA's guidance post this meeting."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

 

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge

John Howes

Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 3550

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

4Reliance (Euronext Growth Listing Sponsor)

Jean-Charles Snoy

 

Degroof Petercam (Liquidity Provider)

Erik De Clippel

 

Backstage Communication

Olivier Duquaine

Gunther De Backer

+32 (0) 2 747 02 60

 

 

+32 (0) 2 287 95 34

 

 

 

+32 (0) 477 504 784

+32 (0) 475 903 909

 

 

 

 

 

 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk 

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

 

About Avion Pharmaceuticals LLC

Avion Pharmaceuticals, LLC, is a specialty pharmaceutical company formed to develop, acquire and market a portfolio of innovative pharmaceutical products in the Women's Health and other therapeutic categories aligned with its mission to improve the quality of patient lives. Avion Pharmaceuticals focuses on identifying opportunities to develop, acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfil unmet medical needs. For more information, visit www.avionrx.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKKCBDDBDBPDD

Quick facts: ImmuPharma PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Immupharma: The Life Sciences Division's Dr Malik says shares are 'oversold'...

The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on ImmuPharma PLC (LON:IMM). Malik examines the company's flagship drug Lupuzor - a treatment for the autoimmune disease Lupus. ImmuPharma recently updated the market on progress within its lupus drug, Lupuzor,...

1 week ago

5 min read